Merck’s antibiotic ZERBAXA® (ceftolozane and tazobactam) has met its primary endpoint of non-inferiority compared with meropenem in a Phase III trial of patients with hospital-acquired and ventilator-associated bacterial pneumonia.
Continuous mass distribution of azithromycin in northern Ethiopia is effective for trachoma prevention but doesn’t eliminate the disease entirely, according to new research.
ViiV Healthcare has announced positive 48-week results from its Phase III ATLAS study of a long-acting, injectable, two-drug regimen for treating HIV.
A study in 20 patients has demonstrated that transplantation followed by antiviral therapy has been successful in patients receiving kidneys from hepatitis C-infected donors.
Glenn Tillotson gives us an overview of the 14th Biennial Congress of the Anaerobe Society of the Americas, including updates on the microbiome and new therapies.
ViiV healthcare has announced results of a 100-week Phase lll program and demonstrated the success of the first two-drug regimen, Juluca®.
The US FDA have approved Krintafel (tafenoquine) for the radical cure of Plasmodium vivax malaria infections, the first approval for such a drug in 50 years.
Globally, shigella is reported to be the third largest cause of diarrheal mortality in the under-fives. We take a look at some of the vaccines that have made it to clinical development and some of the challenges still facing this diarrheal disease.
Experimental HIV-1 vaccine regimen is safe and elicits a robust immune response according to results of a Phase I/IIa clinical trial.
In top-line results from a Phase IIa study, Abivax has reported mixed data, although ABX464 did appear to reduce HIV DNA in blood and rectal samples at a higher dose.
